Tissue-Engineered Grafts & Bioscaffolds
Tissue engineering has reached small human urethral reconstruction studies, including cell-seeded tubular constructs, but these approaches have not replaced established autologous reconstruction. Distinguish a cell-free matrix, a matrix seeded with living cells, and an autologous cultured oral graft: their evidence and regulatory status are different. Most published clinical data concern men; the two-woman urinary bladder matrix report is preliminary evidence, not a validated female pathway.[1][3][27]
The EAU recommends restricting autologous tissue-engineered oral mucosa to clinical trials (strong recommendation). It advises against cell-free engineered grafts in extensive spongiofibrosis, after failed urethroplasty, or for strictures longer than 4 cm (weak recommendation). Commercial availability or national authorization does not establish comparative effectiveness.[28]
For native donors, see Buccal Mucosa Graft, Oral-Lip Mucosa Graft, and Lingual Mucosa Graft.
Acellular (Non-Seeded) Bioscaffolds
Decellularized biological matrices provide a framework for host tissue ingrowth. Preserved extracellular matrix proteins may support attachment and remodeling; they do not guarantee vascularization, urethral regeneration, or freedom from fibrosis. Results depend on the specific scaffold, geometry and recipient bed.[2][3]
Small Intestinal Submucosa (SIS)
Porcine SIS has been studied mainly as an onlay/inlay patch. The following are distinct series or follow-up reports and should not be pooled as independent patients without checking cohort overlap.
| Study | Patients and follow-up | Reported result | Interpretation |
|---|---|---|---|
| Palminteri 2007[4] | 20 men; mean 21 months | 17/20 successful | Three failures involved penile or penile-bulbar repairs; small uncontrolled series. |
| Fiala 2007[5] | 50 men; mean 31.2 months | 40/50 successful; bulbar 9/10, bulbopenile 26/31, penile 5/9 | Overall 80% is not the bulbar-specific result. |
| Palminteri 2012[6] | 25 men; mean 71 months | 19/25 successful; reported failure 14% for strictures under 4 cm, 100% for those over 4 cm | The length comparison is from a small series, not a precise universal threshold. |
| Palminteri 2024[7] | 25 SIS versus 25 buccal grafts after propensity matching | Estimated success at 156 months: 68% versus 83.4% | SIS had poorer outcomes; the authors favored selection below 3 cm, preferably without previous urethrotomy. Matching does not remove all confounding or establish equivalence. |
These studies support caution with longer or poorly vascularized repairs. They do not establish that every short onlay will succeed or that every unseeded tubular construct must fail.[2][8]
Acellular Bladder Matrix (ABM)
The 2008 El-Kassaby comparative study enrolled 30 men. In the reported healthy-bed subgroup, patency was 8/9 with matrix versus 10/10 with buccal mucosa; in the unhealthy-bed subgroup, 2/6 versus 5/5. Small subgroups, prior-treatment burden and source reporting limitations preclude a precise bedside rule based solely on the number of previous operations. The material is a decellularized matrix, not a free living bladder mucosal graft.[9]
Acellular Porcine Urinary Bladder Matrix (UBM) in Women
Ansari and Karram reported two women with loss of the posterior urethral wall. UBM reconstruction was combined with a labial fat-pad flap and biologic pubovaginal sling. One woman became continent and the other improved. The reported mucosal appearance does not prove the graft alone restored function; the concomitant procedures and tiny sample limit inference.[1]
Cell-Seeded Scaffolds
Cell seeding has improved results in several experimental tubular constructs. Whether it is necessary depends on scaffold design, defect geometry and the host environment; an animal result is not a universal engineering law.[3][8][11]
Human Tubularized Constructs: Raya-Rivera 2011
Five boys aged 10–14 years with complex posterior urethral defects received tubular scaffolds seeded with autologous bladder-derived epithelial and smooth-muscle cells. At median 71 months of follow-up (range 36–76), all had patent reconstructions. However, one required an early transurethral incision of an anastomotic narrowing, and another required a pubovesical sling for stress incontinence after pelvic/sphincter injury. This was an uncontrolled feasibility study in children, not evidence of 100% intervention-free success or validation for adult anterior strictures.[27]
Atala Group — Preclinical Tubularized Cell-Seeded Constructs
Orabi's canine study compared 15 cell-seeded and six unseeded 6-cm tubular collagen constructs. Seeded constructs maintained patency while unseeded constructs collapsed in that model. This supports the biological rationale for cell seeding, but does not establish a routine clinical operation or negate newer acellular designs.[10]
Cell Sources Under Investigation
| Source | Potential advantage | Evidence boundary |
|---|---|---|
| Bladder epithelial and smooth-muscle cells | Patient-derived urinary tissue | Requires biopsy and manufacturing; small human feasibility experience. |
| Oral mucosal cells | Small biopsy rather than a large native graft | Clinical observational series exist for cultured oral mucosa. |
| Urine-derived cells | Collection without tissue biopsy | Wu's human-cell work included laboratory culture and mouse implantation; Liu's urethral repair study used rabbits.[13][17] |
| Adipose-derived cells | Investigated paracrine and vascular effects | Hypoxia-conditioned constructs were studied in vitro and in rabbits.[12] |
| Other mesenchymal cells | Experimental scaffold integration | Bilayer scaffold comparisons with buccal grafts remain animal evidence.[16] |
Tissue-Engineered Autologous Oral Mucosa Grafts (TEOMG / MukoCell)
MukoCell is manufactured from a small oral biopsy, with approximately three weeks of laboratory expansion. It reduces the amount of native oral tissue harvested but requires coordinated manufacture, delivery and implantation. Published protocols are not a substitute for current product instructions.[14][18]
Regulatory distinction: the German Paul-Ehrlich-Institut's official notice records an authorization under §4b(3) of the German Medicines Act, dated April 24, 2024, number PEI.A.12195.01.1. This is not an EU-wide CE mark. The German authorization does not establish authorization in other countries, and the EAU trial-only recommendation remains relevant.[29][28]
Clinical Results (Male Series)
| Study | Design and follow-up | Result | Limits |
|---|---|---|---|
| Ram-Liebig 2017[18] | Prospective observational, 99 men at eight centers | Kaplan–Meier success 67.3% at 12 months and 58.2% at 24 months | Only 65 and 39 reached those follow-up visits. The recurrence definition was revised post hoc; no control group. Between-center variation does not isolate a causal learning effect. |
| Barbagli 2018[14] | Retrospective, 38 men; median 55 months | 32/38 successful | No native-graft comparator; selected recurrent anterior strictures. |
| Karapanos 2023[15] | Retrospective, patient-selected graft choice; 77 TEOMG versus 76 native oral grafts | 53/77 (68.8%) versus 60/76 (78.9%); p=0.155; median follow-up 52 versus 53.5 months | Different stricture locations and techniques; a nonsignificant difference does not establish noninferiority. |
In Karapanos, the repeatedly dilated subgroup had success in 5/16 TEOMG versus 10/12 native-graft patients (31.3% versus 83.3%; p=0.006 in the main manuscript). These table-based values differ from the abstract. Oral morbidity was lower with TEOMG, but measurement used a nonvalidated questionnaire without a baseline oral examination. Shorter operative time cannot be attributed entirely to graft harvesting because techniques differed. The TEOMG cases overlap the center's earlier report and must not be counted as an independent new cohort.[15]
Next-Generation Technologies
Bioprinting, extracellular vesicles, modified matrices and mechanically tailored hydrogels remain research platforms. Reviews identify promising mechanisms; they do not establish clinical benefit.[19][20][21]
- Exosome-loaded nanoyarns, modified SIS and multilayer hydrogels: laboratory/animal findings of reduced fibrosis, improved epithelialization or vascularization do not demonstrate durable human scar-free healing.[22][23][24]
- TissueSpan acellular collagen mesh: the 2025 paper reports rabbit and canine development and states that a first-in-human trial had begun. It does not provide a definitive comparative human outcome; initiation should not be confused with a successful trial readout.[25]
- Decellularized human urethra: the 2023 study used tissue from 12 deceased donors to evaluate processing and matrix preservation, not implantation outcomes in 12 patients.[26]
Critical Principles for Clinical Application
- Identify the actual product and configuration. A living mucosal graft, an acellular patch and a cell-seeded tube are different interventions.
- Assess the recipient bed. A salvage indication does not automatically make an experimental scaffold appropriate; dense scarring can be the very reason it performs poorly.
- Read the endpoint. Primary patency, patency after reintervention and continence are different outcomes. Follow-up denominators and overlapping cohorts matter.
- Follow the evidence and local authorization. Regeneration on histology and commercial availability do not establish superiority over established grafts.
Sex-Specific Considerations
Female reconstruction requires direct clinical evidence. A shorter urethra does not guarantee an adequate vascular bed, and prior surgery, irradiation or fistula can compromise adjacent tissue. The small UBM experience cannot be generalized to all female strictures or justify transferring male TEOMG success rates. Established native-tissue options and the specific reconstructive defect remain the clinical comparison.[1]
See Also
- Buccal Mucosa Graft
- Labial Mucosa Graft
- Lingual Mucosa Graft
- Bladder Mucosa Graft
- Liquid / Minced BMG (atlas)
- Female Dorsal Onlay Urethroplasty
- Excision and Primary Anastomosis (male)
References
1. Ansari S, Karram M. "Two Cases of Female Urethral Reconstruction With Acellular Porcine Urinary Bladder Matrix." Int Urogynecol J. 2017;28(8):1257–60. doi:10.1007/s00192-016-3262-7
2. Ribeiro-Filho LA, Sievert KD. "Acellular Matrix in Urethral Reconstruction." Adv Drug Deliv Rev. 2015;82–83:38–46. doi:10.1016/j.addr.2014.11.019
3. de Kemp V, de Graaf P, Fledderus JO, Ruud Bosch JL, de Kort LM. "Tissue Engineering for Human Urethral Reconstruction: Systematic Review of Recent Literature." PLoS One. 2015;10(2):e0118653. doi:10.1371/journal.pone.0118653
4. Palminteri E, Berdondini E, Colombo F, Austoni E. "Small Intestinal Submucosa (SIS) Graft Urethroplasty: Short-Term Results." Eur Urol. 2007;51(6):1695–701. doi:10.1016/j.eururo.2006.12.016
5. Fiala R, Vidlar A, Vrtal R, Belej K, Student V. "Porcine Small Intestinal Submucosa Graft for Repair of Anterior Urethral Strictures." Eur Urol. 2007;51(6):1702–8. doi:10.1016/j.eururo.2007.01.099
6. Palminteri E, Berdondini E, Fusco F, De Nunzio C, Salonia A. "Long-Term Results of Small Intestinal Submucosa Graft in Bulbar Urethral Reconstruction." Urology. 2012;79(3):695–701. doi:10.1016/j.urology.2011.09.055
7. Palminteri E, Toso S, Preto M, et al. "Small Intestinal Submucosa Graft Bulbar Urethroplasty Is a Viable Technique: Results Compared to Buccal Mucosa Graft Urethroplasty After Propensity Score Matching." World J Urol. 2024;42(1):123. doi:10.1007/s00345-024-04795-8
8. Žiaran S, Galambošová M, Danišovič L. "Tissue Engineering of Urethra: Systematic Review of Recent Literature." Exp Biol Med. 2017;242(18):1772–85. doi:10.1177/1535370217731289
9. el-Kassaby A, AbouShwareb T, Atala A. "Randomized Comparative Study Between Buccal Mucosal and Acellular Bladder Matrix Grafts in Complex Anterior Urethral Strictures." J Urol. 2008;179(4):1432–6. doi:10.1016/j.juro.2007.11.101
10. Orabi H, AbouShwareb T, Zhang Y, Yoo JJ, Atala A. "Cell-Seeded Tubularized Scaffolds for Reconstruction of Long Urethral Defects: A Preclinical Study." Eur Urol. 2013;63(3):531–8. doi:10.1016/j.eururo.2012.07.041
11. Atala A. "Experimental and Clinical Experience With Tissue Engineering Techniques for Urethral Reconstruction." Urol Clin North Am. 2002;29(2):485–92. doi:10.1016/s0094-0143(02)00033-2
12. Wan X, Xie MK, Xu H, et al. "Hypoxia-Preconditioned Adipose-Derived Stem Cells Combined With Scaffold Promote Urethral Reconstruction by Upregulation of Angiogenesis and Glycolysis." Stem Cell Res Ther. 2020;11(1):535. doi:10.1186/s13287-020-02052-4
13. Wu S, Liu Y, Bharadwaj S, Atala A, Zhang Y. "Human Urine-Derived Stem Cells Seeded in a Modified 3D Porous Small Intestinal Submucosa Scaffold for Urethral Tissue Engineering." Biomaterials. 2011;32(5):1317–26. doi:10.1016/j.biomaterials.2010.10.006
14. Barbagli G, Akbarov I, Heidenreich A, et al. "Anterior Urethroplasty Using a New Tissue Engineered Oral Mucosa Graft: Surgical Techniques and Outcomes." J Urol. 2018;200(2):448–56. doi:10.1016/j.juro.2018.02.3102
15. Karapanos L, Knorr V, Halbe L, et al. "Comparison of Oral Morbidity and Mid-Term Efficacy of Anterior Urethroplasty Using an Autologous Tissue-Engineered Graft (MukoCell) Versus Native Oral Mucosa Graft." Int J Urol. 2023;30(11):1000–7. doi:10.1111/iju.15247
16. Yudintceva NM, Nashchekina YA, Mikhailova NA, et al. "Urethroplasty With a Bilayered Poly-D,l-Lactide-Co-Ε-Caprolactone Scaffold Seeded With Allogenic Mesenchymal Stem Cells." J Biomed Mater Res B Appl Biomater. 2020;108(3):1010–21. doi:10.1002/jbm.b.34453
17. Liu Y, Ma W, Liu B, et al. "Urethral Reconstruction With Autologous Urine-Derived Stem Cells Seeded in Three-Dimensional Porous Small Intestinal Submucosa in a Rabbit Model." Stem Cell Res Ther. 2017;8(1):63. doi:10.1186/s13287-017-0500-y
18. Ram-Liebig G, Barbagli G, Heidenreich A, et al. "Results of Use of Tissue-Engineered Autologous Oral Mucosa Graft for Urethral Reconstruction: A Multicenter, Prospective, Observational Trial." EBioMedicine. 2017;23:185–92. doi:10.1016/j.ebiom.2017.08.014
19. Habibizadeh M, Mohammadi P, Amirian R, Moradi M, Moradi M. "Engineered Tissues: A Bright Perspective in Urethral Obstruction Regeneration." Tissue Eng Part B Rev. 2025;31(3):209–20. doi:10.1089/ten.TEB.2024.0124
20. Duan L, Wang Z, Fan S, Wang C, Zhang Y. "Research Progress of Biomaterials and Innovative Technologies in Urinary Tissue Engineering." Front Bioeng Biotechnol. 2023;11:1258666. doi:10.3389/fbioe.2023.1258666
21. Sterling J, Hecksher D, Hayden C, et al. "Buccal Mucosa: A Narrative Review — How Does It Work, How Is It Used, What Is Coming Next." Urology. 2026. doi:10.1016/j.urology.2026.03.015
22. Wang L, Cheng W, Zhu J, et al. "Electrospun Nanoyarn and Exosomes of Adipose-Derived Stem Cells for Urethral Regeneration: Evaluations in Vitro and in Vivo." Colloids Surf B Biointerfaces. 2022;209(Pt 2):112218. doi:10.1016/j.colsurfb.2021.112218
23. Huang LP, Liu Y, Li QJ, et al. "A Modified Small Intestinal Submucosa Patch With Multifunction to Promote Scarless Repair and Reinvigoration of Urethra." Adv Healthc Mater. 2023;12(23):e2300519. doi:10.1002/adhm.202300519
24. Jin Y, Wang Y, Yang R, et al. "Multilayered Hydrogel Scaffold Construct With Native Tissue Matched Elastic Modulus: A Regenerative Microenvironment for Urethral Scar-Free Healing." Biomaterials. 2025;312:122711. doi:10.1016/j.biomaterials.2024.122711
25. Vythilingam G, Larsson HM, Yeoh WS, et al. "Off-the-Shelf Implant to Bridge a Urethral Defect: Multicenter 8-Year Journey From Bench to Bed." Urology. 2025;196:294–9. doi:10.1016/j.urology.2024.12.016
26. Kuniakova M, Klein M, Galfiova P, et al. "Decellularization of the Human Urethra for Tissue Engineering Applications." Exp Biol Med. 2023;248(12):1034–42. doi:10.1177/15353702231162092
27. Raya-Rivera A, Esquiliano DR, Yoo JJ, Lopez-Bayghen E, Soker S, Atala A. Tissue-engineered autologous urethras for patients who need reconstruction: an observational study. Lancet. 2011;377:1175–82. doi:10.1016/S0140-6736(10)62354-9
28. European Association of Urology. Urethral Strictures: Tissue Transfer. 2026. Guideline chapter.
29. Paul-Ehrlich-Institut. Bekanntmachung Nr. 518, May 8, 2024; published June 26, 2024. MukoCell authorization under §4b(3) AMG, p. 2. Official notice.